The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- 290 Billion Yen Invested for R&D by Drug Makers Receiving New Drug Development Premium: FPMAJ Survey
November 11, 2013
- Dr Nakagawa of JMA Says Japanese Drug Makers Should Prioritize Domestic Development
November 8, 2013
- CSIMC’s Expert Subcommittee to Present Concrete Plan on Cost-Effective Assessment by End of Year
November 8, 2013
- “Precursor Premium” Bashed by Healthcare Provider, Bill Payer Reps at CSIMC
November 7, 2013
- “Precursor Premium” Proposed at CSIMC Drug Pricing Subcommittee, Yet Further Deliberations Necessary
November 7, 2013
- Online Sales Banned for Three Years after Rx-to-OTC Switch
November 7, 2013
- Chairman Eto of LDP’s Study Group on Drug Industry Policy Calls for “Balance” in Discussions of Special Price Cuts for Long-Listed Drugs
November 7, 2013
- PAFSC’s 2nd Committee on Drugs to Review Afatinib, Brentuximab on November 18
November 7, 2013
- Lawmaker Criticizes Jikei University, Says It Should Return Government Funds
November 6, 2013
- Staff of 1,000 Eyed for PMDA by FY2018: Parliamentary Secretary
November 6, 2013
- 93 MHLW Staff Members Received 2.95 Million Yen from Novartis Pharma from 3rd Quarter of 2008 through 1st Quarter of 2013
November 6, 2013
- Checking of Remaining Drugs Would Save 9.7 Billion Yen Annually: Estimate by Health and Labor Science Research Group
November 1, 2013
- New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium
October 31, 2013
- MHLW Investigating Whether Advertising for Diovan Violates PAL
October 31, 2013
- Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo
October 30, 2013
- Causal Relationship between Tamiflu and Abnormal Behavior Not Identified: PAFSC Subcommittee
October 30, 2013
- Health Ministry Subcommittees Agree to Continue Suspending Recommendation for HPV Vaccines
October 30, 2013
- MHLW Discussing OTC Status for Certain In Vitro Diagnostics
October 30, 2013
- 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment
October 30, 2013
- MHLW Rejects 2 Applicants for Cell-Based Flu Vaccine Subsidy Project
October 29, 2013
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…